Artelo Biosciences Announces Board and Compensation Changes

Ticker: ARTL · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1621221

Sentiment: neutral

Topics: management-change, compensation, governance

Related Tickers: ARLO

TL;DR

Artelo Biosciences shakes up board and exec pay. Big changes coming?

AI Summary

Artelo Biosciences, Inc. announced on October 26, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in leadership and compensation can introduce uncertainty about the company's future direction and stability.

Key Players & Entities

FAQ

What specific reasons were given for the departure of directors or officers?

The filing indicates "Departure of Directors or Certain Officers" as an item, but the specific reasons for each departure are not detailed in the provided text.

Who are the newly elected directors?

The filing mentions the "Election of Directors" but does not list the names of the newly elected individuals in the provided text.

What are the key changes in the compensatory arrangements for certain officers?

The filing lists "Compensatory Arrangements of Certain Officers" as an item, but the specific details of these arrangements are not included in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on October 26, 2025.

What is the company's state of incorporation and fiscal year end?

The company is incorporated in Nevada and its fiscal year ends on December 31.

Filing Stats: 1,455 words · 6 min read · ~5 pages · Grade level 14.2 · Accepted 2025-10-27 08:00:51

Key Financial Figures

Filing Documents

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Spring Employment Agreement. 10.2 Employment Agreement Amendment. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARTELO BIOSCIENCES, INC. Date: October 27, 2025 By: /s/ Gregory D. Gorgas Gregory D. Gorgas President & Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing